LPL Financial
PTGX icon

LPL Financial’s Protagonist Therapeutics PTGX Stock Holding History

LPL Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$484K Buy
3,946
+1,153
+41% +$120K ﹤0.01% 5055
2026
Q1 		$294K Sell
2,793
-472
-14% -$41.8K ﹤0.01% 5197
2025
Q4 		$285K Sell
3,265
-1,729
-35% -$142K ﹤0.01% 5183
2025
Q3 		$332K Buy
4,994
+176
+4% +$10K ﹤0.01% 4978
2025
Q2 		$266K Sell
4,818
-70
-1% -$3.36K ﹤0.01% 4859
2025
Q1 		$236K Buy
+4,888
New +$205K ﹤0.01% 4741

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

LPL Financial's PTGX Position: Q2 2026 in Review

LPL Financial increased its Protagonist Therapeutics (PTGX) stake by 41% in Q2 2026, buying an estimated $120K and bringing the position to 3,946 shares worth $484K. The position accounts for ﹤0.01% of the portfolio, ranked #5055.

LPL Financial first reported a position in PTGX in Q1 2025 and has held it in 6 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • LPL Financial held 3,946 shares of Protagonist Therapeutics worth $484K as of Q2 2026.
  • LPL Financial bought 1,153 Protagonist Therapeutics shares in Q2 2026, an estimated $120K.
  • Protagonist Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5055 holding.
  • LPL Financial first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.